IL17A and inflammatory skin disease: Furthermore, future studies should explore the potential neuroprotective effects of biologic and anti-inflammatory agents used in skin inflammatory diseases, currently psoriasis, as emerging evidence suggests that modulation of systemic inflammation through IL-17, IL-23, or TNF-α inhibition may attenuate neuroinflammatory pathways and reduce the risk or progression of neurodegeneration.